Drug intelligence / Profile preview

follitropin alfa biosimilar DA-3801

Development stage: Phase 3
Lead developer: Dong-A ST
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

DA-3801 is a recombinant human follicle-stimulating hormone (FSH) biosimilar to follitropin alpha (Gonal-F). It is used for controlled ovarian hyperstimulation (COH) in women undergoing assisted reproductive technology (ART). Clinical studies have demonstrated that DA-3801 is not inferior to follitropin alpha in terms of efficacy and safety, with comparable pregnancy and implantation rates. In some studies, DA-3801 showed a lower total dose requirement and shorter stimulation duration compared to the reference product.

Brand names: GonadopinGonadorphinFollitrope

Targets

FSHR (Follicle-stimulating hormone receptor)

Beyond the preview

Go deeper on follitropin alfa biosimilar DA-3801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on follitropin alfa biosimilar DA-3801.

Explore the full profile